Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease / 华中科技大学学报(医学)(英德文版)
Journal of Huazhong University of Science and Technology (Medical Sciences)
; (6): 333-336, 2015.
Article
en En
| WPRIM
| ID: wpr-331064
Biblioteca responsable:
WPRO
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease and it represents the hepatic manifestation of metabolic syndrome, which includes type 2 diabetes mellitus (T2DM), dyslipidemia, central obesity and hypertension. Glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors were widely used to treat T2DM. These agents improve glycemic control, promote weight loss and improve lipid metabolism. Recent studies have demonstrated that the GLP-1 receptor (GLP-1R) is present and functional in human and rat hepatocytes. In this review, we present data from animal researches and human clinical studies that showed GLP-1 analogues and DPP-4 inhibitors can decrease hepatic triglyceride (TG) content and improve hepatic steatosis, although some effects could be a result of improvements in metabolic parameters. Multiple hepatocyte signal transduction pathways and mRNA from key enzymes in fatty acid metabolism appear to be activated by GLP-1 and its analogues. Thus, the data support the need for more rigorous prospective clinical trials to further investigate the potential of incretin therapies to treat patients with NAFLD.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Farmacología
/
Triglicéridos
/
Ensayos Clínicos como Asunto
/
Usos Terapéuticos
/
Quimioterapia
/
Péptido 1 Similar al Glucagón
/
Metabolismo de los Lípidos
/
Inhibidores de la Dipeptidil-Peptidasa IV
/
Enfermedad del Hígado Graso no Alcohólico
/
Hipoglucemiantes
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Journal of Huazhong University of Science and Technology (Medical Sciences)
Año:
2015
Tipo del documento:
Article